The French Cochlear Implant Registry (EPIIC): Cochlear implant candidacy assessment of off-label indications.


Journal

European annals of otorhinolaryngology, head and neck diseases
ISSN: 1879-730X
Titre abrégé: Eur Ann Otorhinolaryngol Head Neck Dis
Pays: France
ID NLM: 101531465

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 9 8 2020
medline: 9 9 2021
entrez: 9 8 2020
Statut: ppublish

Résumé

Evaluate in France the outcomes of cochlear implantation outside the selection criteria, off-label. This is a prospective cohort study including adults and children having received a cochlear implant (CI) in an off-label indication, that is outside the criteria established by the "Haute Autorité de santé (HAS)" in 2012. The data was collected from the "EPIIC" registry on recipients who received CIs in France between 2011 and 2014. Speech audiometry was performed at 60dB preimplantation and after one year of CI use, as well as an evaluation of the scores of the quality of life with the APHAB questionnaire, the scores for CAP and the professional/academic status in pre- and post-implantation conditions. Major and minor complications at surgery have been recorded. In total, 590 patients (447 adults and 143 children) with an off-label indication for CIs were included in this study from the EPIIC registry (11.7% of the whole cohort of EPIIC). For adults, the median percentage of comprehension using monosyllabic word lists was 41% in preimplantation condition versus 53% after one year of CI use (P<0.001) and 60% versus 71% in dissyllabic word lists (P<0.001). The CAP scores were 5 versus 6 in pre- and post-implantation conditions respectively (P<0.001) and the APHAB scores were statistically lower after implantation (P<0.001). In the children cohort, the median percentage of comprehension using monosyllabic word lists was 51% in preimplantation condition and 65% after CI (P<0.001), and 48% versus 82% (P<0.001) for dissyllabic word lists. The CAP scores were 5 versus 7 respectively in pre- and post-CI conditions (P<0.001). Thirty-two minor complications (5.4%) and 17 major complications (2.8%) were reported in our panel of off-label indication patients. These results suggest that a revision of the cochlear implantation candidacy criteria is necessary to allow more patients with severe or asymmetric hearing loss to benefit from a CI when there is an impact on quality of life despite the use of an optimal hearing aid.

Identifiants

pubmed: 32763084
pii: S1879-7296(20)30178-2
doi: 10.1016/j.anorl.2020.07.012
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

S27-S35

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

R Quatre (R)

Service d'ORL, CHU de Grenoble, 38700 La Tronche, France.

C Fabre (C)

Service d'ORL, CHU de Grenoble, 38700 La Tronche, France.

K Aubry (K)

CHU de Limoges, Limoges, France.

P Bordure (P)

CHU de Nantes, Nantes, France.

A Bozorg-Grayeli (A)

CHU de Dijon, Dijon, France.

O Deguine (O)

CHU de Toulouse, Toulouse, France.

C Eyermann (C)

CHU de Strasbourg, Strasbourg, France.

V Franco-Vidal (V)

CHU de Bordeaux, Bordeaux, France.

B Godey (B)

CHU de Rennes, Rennes, France.

N Guevara (N)

CHU de Nice, Nice, France.

A Karkas (A)

CHU de Saint-Étienne, Saint-Étienne, France.

N Klopp (N)

CHU d'Amiens, Amiens, France.

M Labrousse (M)

CHU de Reims, Reims, France.

J-P Lebreton (JP)

CHU de Poitiers, Poitiers, France.

Y Lerosey (Y)

CHU de Rouen, Rouen, France.

E Lescanne (E)

CHU de Tours, Tours, France.

N Loundon (N)

Hôpital Necker, Paris, France.

R Marianowski (R)

CHU de Brest, Brest, France.

F Merklen (F)

CHU de Montpellier, Montpellier, France.

K Mezouaghi (K)

CH de La Réunion, Saint-Denis, Réunion.

T Mom (T)

CHU de Clermont-Ferrand, Clermont-Ferrand, France.

S Moreau (S)

CHU de Caen, Caen, France.

I Mosnier (I)

Hôpital Pitié-Salpétrière, Paris, France.

N Noël-Petroff (N)

Hôpital Robert-Debré, Paris, France.

C Parietti-Winkler (C)

CHU de Nantes, Nantes, France.

P Piller (P)

CH de Nouméa, Nouméa, Nouvelle-Calédonie.

C Poncet (C)

Hôpital Rothschild, Paris, France.

E Radafy (E)

CH du Lamentin, Martinique, Guadeloupe.

S Roman (S)

CHU de Marseille, Marseille, France.

S Roux-Vaillard (S)

CHU d'Angers, Angers, France.

L Tavernier (L)

CHU de Besançon, Besançon, France.

E Truy (E)

CHU de Lyon, Lyon, France.

C Vincent (C)

CHU de Lille, Lille, France.

S Schmerber (S)

Service d'ORL, CHU de Grenoble, 38700 La Tronche, France. Electronic address: SSchmerber@chu-grenoble.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH